Autonomix Medical, Inc. Granted New European Patent for First-in-Class Catheter-Based Technology
Autonomix Medical (NASDAQ: AMIX) has been granted European Patent No. 3,697,298 for its medical device technology focused on capturing and processing physiological signals. The patent strengthens the company's intellectual property portfolio, which now includes 80 issued patents and 40 pending applications.
The patented technology features a catheter-based microchip sensing array designed to detect and differentiate neural signals with enhanced sensitivity. The system includes distributed signal acquisition modules for neural mapping procedures, with capabilities spanning coronary artery/vagal nerve mapping, renal mapping, and various other applications in robotic prosthetics and neurotherapy.
Autonomix Medical (NASDAQ: AMIX) ha ottenuto il brevetto europeo n. 3,697,298 per la sua tecnologia medicale dedicata alla cattura e all'elaborazione dei segnali fisiologici. Il brevetto rafforza il portafoglio di proprietà intellettuale della società, che conta ora 80 brevetti rilasciati e 40 domande in corso.
La tecnologia brevettata prevede un array di sensori a microchip inserito in un catetere, progettato per rilevare e distinguere segnali neurali con maggiore sensibilità. Il sistema comprende moduli distribuiti per l'acquisizione dei segnali utili nelle procedure di mappatura neurale, con applicazioni che spaziano dalla mappatura dell'arteria coronaria/nervo vago e renale fino a numerosi altri impieghi in protesi robotiche e terapie neurochirurgiche.
Autonomix Medical (NASDAQ: AMIX) ha obtenido la Patente Europea nº 3,697,298 para su tecnología médica centrada en la captura y el procesamiento de señales fisiológicas. La patente refuerza la cartera de propiedad intelectual de la compañía, que ahora incluye 80 patentes concedidas y 40 solicitudes en trámite.
La tecnología patentada incorpora una Matriz de sensores con microchip en catéter diseñada para detectar y diferenciar señales neuronales con mayor sensibilidad. El sistema incluye módulos de adquisición de señales distribuidos para procedimientos de mapeo neural, con capacidades que abarcan el mapeo de arterias coronarias/ nervio vago, el mapeo renal y diversas aplicaciones en prótesis robóticas y neuroterapia.
Autonomix Medical (NASDAQ: AMIX)가 생리 신호의 포착 및 처리를 중심으로 한 의료기술에 대해 유럽 특허 번호 3,697,298을 획득했습니다. 이번 특허는 회사의 지적재산 포트폴리오를 강화하며, 현재 등록된 특허 80건과 출원 중인 신청 40건을 보유하고 있습니다.
특허 기술은 향상된 감도로 신경 신호를 검출하고 구분하도록 설계된 카테터 기반의 마이크로칩 센서 어레이를 특징으로 합니다. 이 시스템은 신경맵핑 절차를 위한 분산형 신호 획득 모듈을 포함하며, 관상동맥/미주신경 맵핑, 신장 맵핑 및 로봇 보철과 신경치료 등 다양한 응용 분야에 적용됩니다.
Autonomix Medical (NASDAQ: AMIX) s'est vu délivrer le brevet européen n° 3,697,298 pour sa technologie médicale dédiée à la capture et au traitement des signaux physiologiques. Ce brevet renforce le portefeuille de propriété intellectuelle de la société, qui comprend désormais 80 brevets délivrés et 40 demandes en cours.
La technologie brevetée comporte une matrice de capteurs sur micro-puce intégrée à un cathéter, conçue pour détecter et différencier les signaux neuronaux avec une sensibilité accrue. Le système inclut des modules d'acquisition de signaux distribués pour les procédures de cartographie neuronale, avec des capacités allant de la cartographie des artères coronaires/du nerf vague et rénale à diverses autres applications en prothèses robotiques et neurothérapie.
Autonomix Medical (NASDAQ: AMIX) wurde das europäische Patent Nr. 3,697,298 für seine Medizintechnik zur Erfassung und Verarbeitung physiologischer Signale erteilt. Das Patent stärkt das geistige Eigentum des Unternehmens, das nun 80 erteilte Patente und 40 anhängige Anmeldungen umfasst.
Die patentierte Technologie umfasst ein katheterbasiertes Sensor-Array mit Mikrochip, das entwickelt wurde, um neuronale Signale mit erhöhter Empfindlichkeit zu erfassen und zu unterscheiden. Das System enthält verteilte Signalaufnahme-Module für neural-mapping Verfahren und bietet Funktionen für die Kartierung der Koronararterien/ des Vagusnervs, Nierenkartierungen sowie verschiedene weitere Anwendungen in robotischen Prothesen und Neurotherapien.
- None.
- Commercialization timeline remains uncertain
- Technology still in development phase without current revenue generation
Insights
Autonomix secures strategic European patent for nerve-sensing technology, strengthening its competitive position in multiple billion-dollar medical markets.
Autonomix Medical's newly granted European patent (No. 3,697,298) significantly reinforces the company's intellectual property portfolio, which now includes 80 issued patents and 40 pending applications. This particular patent protects their proprietary circuitry for capturing and processing physiological signals in real-time - a critical competitive advantage in the medical device sector.
The technology described features distributed signal acquisition modules that enhance signal capture during neural mapping procedures, with components that locally capture, amplify, digitize, and transmit physiological signals from sensors along a catheter. The system's technical advantages include miniaturization, precision, and noise reduction - all vital for high-quality neural signal detection.
What makes this patent particularly valuable is its broad application potential across multiple high-value therapeutic areas: coronary artery/vagal nerve mapping, arterial/renal mapping, bladder/lower urinary tract applications, robotic prosthetics, and central nervous system monitoring. This diversification across multiple billion-dollar markets creates multiple potential revenue streams.
The company's platform technology combines a catheter-based microchip sensing array with proprietary RF ablation capabilities, creating a "sense, treat and verify" approach to precision nerve-targeted treatments. This integrated approach addresses a key challenge in interventional procedures - the ability to precisely identify target nerves before treatment and verify treatment success afterward.
This patent grant in Europe expands Autonomix's global protection for its technology platform beyond the U.S. market, potentially increasing the company's addressable market and future partnering opportunities as they advance toward commercialization.
Global patent estate encompasses 80 issued patents and 40 pending patent applications
Strengthens strategic position in a multi-billion-dollar market opportunity across cardiovascular, renal, and other high-burden diseases
THE WOODLANDS, TX, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that European Patent Office (EPO) has granted Patent No. 3,697,298 (the ‘298 patent), titled, “Medical Device with Circuitry for Capturing and Processing Physiological Signals.” The newly issued ‘298 patent relates to use of its proprietary technology to collect and process sensing data for real-time physiological monitoring with broad application use that includes coronary artery/vagal nerve mapping, arterial/renal mapping, bladder/lower urinary tract applications, robotic prosthetics and implants, and central nervous system monitoring for neurotherapy.
“By protecting our proprietary circuitry for capturing and processing physiological signals in real time, we continue to strengthen the competitive moat around our technology which has broad, high-value applications across a number of indications. The ‘298 patent combined with 80 other issued patents positions us to capture opportunities across multiple multi-billion-dollar markets, create diverse revenue streams, and expand our global footprint as we advance toward potential commercialization in the future,” commented Brad Hauser, CEO of Autonomix.
In particular, the ‘298 patent relates generally to medical devices and methods for acquiring and processing physiological signals and provides a system of distributed signal acquisition modules that enhance signal capture and data integrity during neural mapping procedures. These modules locally capture, amplify, digitize, and transmit physiological signals from sensors arranged along the catheter. Key elements of the technology include, but are not limited to, multiple processing modules paired to one or more sensor, data acquisition logic, analog and digital signal processing circuitry positioned at the source, efficient data transmitting, and a modular microchip design, along with technical advantages that range from miniaturization to precision to noise reduction.
Autonomix’s first-in-class technology platform utilizes a catheter-based microchip sensing array antenna that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary RF ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology.
For more information about the Company’s technology, please visit autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer and other indications and the ability of our patents to strengthen our strategic position. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com
FAQ
What is the significance of Autonomix Medical's new European patent?
How many patents does Autonomix Medical (AMIX) currently hold?
What medical conditions can Autonomix Medical's technology potentially treat?
How does Autonomix Medical's catheter-based technology work?
What are the key features of Autonomix's new patented technology?
